2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Metabolic Enzyme/Protease
    Vitamin D Related/Nuclear Receptor
  4. PPAR
  5. PPARβ/δ Isoform
  6. PPARβ/δ Antagonist

PPARβ/δ Antagonist

PPARβ/δ Antagonists (7):

Cat. No. Product Name Effect Purity
  • HY-16578
    GW9662
    		Antagonist 99.87%
    GW9662 is a potent and selective PPARγ antagonist with an IC50 of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively.
  • HY-13202
    T0070907
    		Antagonist 99.98%
    T0070907 is a potent PPARγ antagonist with a Ki of 1 nM.
  • HY-163436
    F44-A13
    		Antagonist
    F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC50 value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders.
  • HY-12377
    GSK0660
    		Antagonist 99.19%
    GSK0660 is a potent antagonist of PPARβ and PPARδ, with IC50s of 155 nM for both isoforms.
  • HY-15577
    GSK3787
    		Antagonist 98.03%
    GSK3787 is a selective and irreversible peroxisome proliferator-activated receptor δ (PPARδ) antagonist with pIC50 of 6.6.
  • HY-19737A
    DG172 dihydrochloride
    		Antagonist 99.03%
    DG172 dihydrochloride is a selective PPARβ/δ antagonist, with an IC50 of 27 nM.
  • HY-114263
    NXT629
    		Antagonist 99.20%
    NXT629 is a potent, selective, and competitive PPAR-α antagonist, with an IC50 of 77 nM for human PPARα, shows high selectivity over other nuclear hormone receptor, such as PPARδ, PPARγ, ERβ, GR and TRβ, IC50s are 6.0, 15, 15.2, 32.5 and >100 μM, respectively. NXT629 has potent anti-tumor activity and inhibits experimental metastasis of cancer cell in animal models.